Overview
H3 Biomedicine, the U.S.-based precision oncology research and development subsidiary of Eisai Co., Ltd., is focused on advancing drugs from bench to bedside. Uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics, H3 Biomedicine is developing a pipeline of highly targeted medicines that have the potential to impact the future of cancer care and treatment. For more information, please visit our website at www.H3Biomedicine.com